Vaccination strategies for lymphomas

被引：4

作者：

Mohammed M. Dar

Larry W. Kwak

机构：

[1] National Cancer Institute-Frederick, Frederick, MD 21702-1201

来源：

Current Oncology Reports | 2003年 / 5卷 / 5期

关键词：

Follicular Lymphoma; Antitumor Immunity; Vaccination Strategy; Keyhole Limpet Hemocyanin; Variable Heavy;

D O I：

10.1007/s11912-003-0022-x

中图分类号：

学科分类号：

摘要：

Vaccination strategies for lymphomas were developed along with one of the first recognized tumor-specific targets, the clonal antigen receptor, composed of unique variable regions known as idiotypes. Human clinical trials of idiotype vaccination have benefited from highly concordant animal models, leading to sequential improvements in design. Evidence of the clinical benefit of idiotype vaccines is strong but formally unproven. Significant progress has been made in our understanding of the basic mechanisms underlying the induction of immune responses, which has led to a proliferation of rationally designed immunotherapeutic strategies. Current research efforts include the development of more convenient methods to produce individual idiotype vaccines, the establishment of definitive proof for clinical efficacy, and the implementation of alternative vaccination strategies, including genetic vaccination and genetically or immunologically modified autologous tumor cells and dendritic cells. Copyright © 2003 by Current Science Inc.

引用

页码：380 / 386

页数：6

共 64 条

[1]

Jemal A., Murray T., Samuels A., Et al., Cancer statistics 2003, CA Cancer J. Clin., 53, pp. 5-26, (2003)

[2]

Devesa S.S., Fears T., Non-Hodgkin's lymphoma time trends: United States and international data, Cancer Res, 52, SUPPL., (1992)

[3]

Lynch R.G., Graff R.J., Sirisinha S., Et al., Myeloma proteins as tumor-specific transplantation antigens, Proc. Natl. Acad. Sci. U S A, 69, pp. 1540-1544, (1972)

[4]

Sugai S., Palmer D.W., Talal N., Et al., Protective and cellular immune response to idiotypic determinants on cells from a spontaneous lymphoma of NZB/NZW F1 mice, J. Exp. Med., 140, pp. 1547-1558, (1974)

[5]

Freedman P.M., Autry J.R., Tokuda S., Et al., Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein, J. Natl. Cancer Inst., 56, pp. 735-740, (1976)

[6]

Stevenson G.T., Elliott E.V., Stevenson F.K., Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target, Fed. Proc., 36, pp. 2268-2271, (1977)

[7]

Jorgensen T., Gaudernack G., Jannestad K., Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315, Scand. J. Immunol., 11, pp. 29-35, (1980)

[8]

Kaminski M.S., Kitamura K., Maloney D.G., Et al., Idiotype vaccination against murine B cell lymphoma: Inhibition of tumor immunity by free idiotype protein, J. Immunol., 138, pp. 1289-1296, (1987)

[9]

Kwak L.W., Campbell M.J., Czerwinski D.K., Et al., Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors, N. Engl. J. Med., 327, pp. 1209-1215, (1992)

[10]

Hsu F.J., Caspar C.B., Czerwinski D., Et al., Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial, Blood, 89, pp. 3129-3135, (1997)

← 1 2 3 4 5 6 7 →